Get the Stockscreener App
9.1242
5.07%
0.4542
Tilray Brands Inc stock is traded at $9.1242, with a volume of 1.92M.
It is up +5.07% in the last 24 hours and down -12.57% over the past month.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
See More
Previous Close:
$8.67
Open:
$8.79
24h Volume:
1.92M
Relative Volume:
0.20
Market Cap:
$1.06B
Revenue:
$829.22M
Net Income/Loss:
$-248.96M
P/E Ratio:
-30.41
EPS:
-0.3
Net Cash Flow:
$-92.10M
1W Performance:
-6.18%
1M Performance:
-12.57%
6M Performance:
+15.92%
1Y Performance:
-19.38%
1-Day Range:
$8.76
$9.18
1-Week Range:
$8.61
$9.6799
52-Week Range:
$3.507
$23.20
Tilray Brands Inc Stock (TLRY) Company Profile
Name
Tilray Brands Inc
Sector
Phone
519.322.8800
Address
655 MADISON AVENUE, NEW YORK
Compare TLRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLRY
Tilray Brands Inc
|
9.125 | 1.01B | 829.22M | -248.96M | -92.10M | -0.30 |
|
ZTS
Zoetis Inc
|
125.40 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.02 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.62 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
469.39 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Tilray Brands Inc Stock (TLRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Reiterated | Alliance Global Partners | Neutral |
| Nov-02-22 | Initiated | Bernstein | Mkt Perform |
| Jul-29-22 | Downgrade | The Benchmark Company | Hold → Sell |
| Mar-04-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Nov-18-21 | Initiated | Barclays | Underweight |
| Nov-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-11-21 | Downgrade | CIBC | Sector Outperform → Neutral |
| Jun-03-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| May-11-21 | Resumed | Cowen | Outperform |
| May-07-21 | Resumed | Jefferies | Buy |
| May-06-21 | Initiated | Canaccord Genuity | Buy |
| Apr-28-21 | Resumed | BofA Securities | Buy |
| Feb-18-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-18-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Nov-16-20 | Downgrade | Jefferies | Hold → Underperform |
| Nov-11-20 | Downgrade | Stifel | Hold → Sell |
| Oct-01-20 | Reiterated | MKM Partners | Neutral |
| Sep-21-20 | Upgrade | Jefferies | Underperform → Hold |
| May-12-20 | Reiterated | The Benchmark Company | Buy |
| Apr-16-20 | Downgrade | Jefferies | Hold → Underperform |
| Apr-09-20 | Downgrade | Consumer Edge Research | Overweight → Equal Weight |
| Feb-24-20 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-13-20 | Initiated | BofA/Merrill | Neutral |
| Nov-13-19 | Reiterated | The Benchmark Company | Buy |
| Nov-05-19 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-22-19 | Reiterated | Piper Jaffray | Overweight |
| Sep-20-19 | Initiated | MKM Partners | Neutral |
| Aug-14-19 | Reiterated | The Benchmark Company | Buy |
| Jul-17-19 | Initiated | Ladenburg Thalmann | Neutral |
| Jun-28-19 | Initiated | Consumer Edge Research | Overweight |
| Jun-06-19 | Initiated | Stifel | Hold |
| Jun-05-19 | Initiated | Oppenheimer | Perform |
| May-15-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-13-19 | Initiated | Alliance Global Partners | Neutral |
View All
Tilray Brands Inc Stock (TLRY) Latest News
What's Going On With Tilray Stock Today? - Benzinga
Tilray (TLRY) Expands Medical Cannabis Operations in Italy - GuruFocus
New 9% 'Big Trip' IPA rides Southeast double-IPA demand - Stock Titan
Tilray Medical Launches Tilray Medical Italia, Expanding Presence in Italy's Medical Cannabis Market - Quiver Quantitative
Tilray brings prescription cannabis oils and flower to Italian patients - Stock Titan
Promising Cannabis Stocks To Watch TodayJanuary 21st - MarketBeat
Tilray’s Financial Turnaround: Losses Narrow Amidst Strategic Shifts - AD HOC NEWS
Tilray Brands Just Posted Record Numbers for Q2. Is the Stock a Buy? - AOL.com
Tilray Brands (NASDAQ:TLRY) Trading Down 7.4% Following Analyst Downgrade - MarketBeat
Tilray Brands (TLRY): Roth Capital Lowers Price Target to $10 | - GuruFocus
Tilray Brands (NASDAQ:TLRY) Given New $10.00 Price Target at Roth Capital - MarketBeat
Mixed Signals for Tilray: Record Revenue Meets Analyst Caution - AD HOC NEWS
How Tilray Brands Is Acting on Its Vast International Opportunity - The Globe and Mail
Tilray Brands Reports $218 Million Q2 Revenue, Market Reacts Positively - Intellectia AI
Tilray Brands, Inc. (NASDAQ:TLRY) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat
This Beaten-Down Stock Just Posted Record Revenue. Is It Finally Time to Buy? - Finviz
Top Cannabis Stocks To Follow TodayJanuary 19th - MarketBeat
Tilray’s Mixed Quarter: Record Revenue Overshadowed by Widening Losses - AD HOC NEWS
Tilray. Buy, Sell or Hold? - Cantech Letter
Trump's Cannabis Rescheduling Order Could Finally Kill A Crushing Tax Rule And Transform US Weed Stocks, Says Expert - Benzinga
Tilray Shares Face Headwinds Following Quarterly Report - AD HOC NEWS
Tilray Shares Face Mounting Investor Skepticism Despite Revenue Gains - AD HOC NEWS
Promising Cannabis Stocks To Keep An Eye OnJanuary 18th - MarketBeat
Tilray’s Financial Paradox: Record Revenue Amid Persistent Losses - AD HOC NEWS
Best Cannabis Stocks To ResearchJanuary 17th - MarketBeat
Tilray’s Financial Results Reveal Deepening Concerns for Investors - AD HOC NEWS
Tilray anticipates $150M global medical cannabis revenue run rate as international expansion accelerates - MSN
Tilray Brands (NASDAQ:TLRY) Stock Price Down 2.6%Time to Sell? - MarketBeat
Top Cannabis Stocks To Add to Your WatchlistJanuary 16th - MarketBeat
Promising Cannabis Stocks To Add to Your WatchlistJanuary 3rd - MarketBeat
Village Farms Stock More Than Doubles in 6 Months: How to Play? - The Globe and Mail
Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 30% Price Drop - simplywall.st
Tilray’s Profitability Concerns Overshadow Record Revenue - AD HOC NEWS
Tilray Continues to Gain in Canada and International Medical, but We're Skeptical of US Prospects - Morningstar
Tilray Brands (NASDAQ:TLRY) Shares Down 1.9%What's Next? - MarketBeat
Best Cannabis Stocks To Watch TodayJanuary 15th - MarketBeat
Tilray Brands (NASDAQ:TLRY) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Tilray Brands (NASDAQ:TLRY) Trading Up 5.4%Here's What Happened - MarketBeat
Cannabis Stocks To Watch TodayJanuary 14th - MarketBeat
Tilray Posts Record Revenue Amid Diverging Segment Performance - AD HOC NEWS
What's Next for Tilray Brands After Posting Record Q2 Revenues? - The Globe and Mail
Tilray Brands (TSX:TLRY) Price Target Decreased by 18.79% to 19.17 - Nasdaq
Investment Recap: Why Tilray Brands Inc stock is seen as undervaluedJuly 2025 Summary & Detailed Earnings Play Alerts - moha.gov.vn
Top Cannabis Stocks To ResearchJanuary 13th - MarketBeat
Best Cannabis Stocks To Follow TodayJanuary 8th - MarketBeat
Should You Buy, Sell or Hold TLRY Stock Post Q2 Earnings? - The Globe and Mail
Legal Cannabis Market Set for Dynamic Growth with Key Players Aurora Cannabis • Cronos Group • Tilray Brands - openPR.com
This Under-$10 Growth Stock May Be Better Positioned Than Investors Realize - Barchart.com
Tilray Brands (XTRA:2HQ) Price Target Decreased by 23.26% to 11.31 - Nasdaq
Tilray Reports Historic Quarterly Revenue Amid Strategic Shifts - AD HOC NEWS
Tilray Brands (NASDAQ:TLRY) Shares Up 1.3%Still a Buy? - MarketBeat
Tilray Brands Inc Stock (TLRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tilray Brands Inc Stock (TLRY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SIMON IRWIN D | President and CEO |
Jul 31 '25 |
Option Exercise |
0.58 |
706,216 |
409,605 |
5,200,788 |
| Merton Carl A | Chief Financial Officer |
Jul 31 '25 |
Option Exercise |
0.58 |
93,928 |
54,478 |
970,279 |
| Gendel Mitchell | Global General Counsel |
Jul 31 '25 |
Option Exercise |
0.58 |
93,928 |
54,478 |
742,069 |
| Gendel Mitchell | Global General Counsel |
Jul 31 '25 |
Buy |
0.58 |
6,000 |
3,496 |
698,287 |
| FALTISCHEK DENISE M | Chief Strategy Officer |
Jul 31 '25 |
Option Exercise |
0.58 |
93,928 |
54,478 |
874,564 |
| FALTISCHEK DENISE M | Chief Strategy Officer |
Jul 30 '25 |
Option Exercise |
0.61 |
261,194 |
159,328 |
919,069 |
| Herhalt Johann Michael | Director |
Jul 30 '25 |
Option Exercise |
0.61 |
124,378 |
75,871 |
239,930 |
| Looney Thomas P. | Director |
Jul 30 '25 |
Option Exercise |
0.61 |
124,378 |
75,871 |
354,416 |
| Hopkinson David G. | Director |
Jul 30 '25 |
Option Exercise |
0.61 |
124,378 |
75,871 |
335,563 |
| Clanachan David F | Director |
Jul 30 '25 |
Option Exercise |
0.61 |
124,378 |
75,871 |
236,880 |
3.14%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):